Nkarta, Inc.

9 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2038

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 15, 2027.

Recent changes

1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 11,365,236	Truncated NKG2D Chimeric Receptors and Uses Thereof in Natural Killer Cell Immunotherapy In force Term ends Mar 27, 2038 · High confidence	In force	Term ends Mar 27, 2038	High confidence
US 12,351,617	Immune Cells Comprising Truncated NKG2D Chimeric Receptors In force Term ends Mar 27, 2038 · High confidence	In force	Term ends Mar 27, 2038	High confidence
US 11,141,436	Immune Cells Engineered to Express CD19-Directed Chimeric Antigen Receptors and Uses Thereof in Immunotherapy In force Term ends Mar 3, 2040 · Medium confidence	In force	Term ends Mar 3, 2040	Medium confidence
US 11,154,575	Cancer Immunotherapy Using CD19-Directed Chimeric Antigen Receptors In force Term ends Mar 3, 2040 · Medium confidence	In force	Term ends Mar 3, 2040	Medium confidence
US 11,253,547	CD19-Directed Chimeric Antigen Receptors and Uses Thereof in Immunotherapy In force Term ends Mar 3, 2040 · Medium confidence	In force	Term ends Mar 3, 2040	Medium confidence
US 12,398,187	CD19-Directed Chimeric Antigen Receptors and Uses Thereof in Immunotherapy In force Term ends Mar 3, 2040 · Medium confidence	In force	Term ends Mar 3, 2040	Medium confidence
US 12,012,458	Genetically Modified Natural Killer Cells for CD70-Directed Cancer Immunotherapy In force Term ends Feb 5, 2042 · High confidence	In force	Term ends Feb 5, 2042	High confidence
US 12,790,384	Methods and Compositions for Enhanced Expansion and Cytotoxicity of Natural Killer Cells In force Term ends Mar 22, 2043 · High confidence	In force	Term ends Mar 22, 2043	High confidence
US 12,590,148	Methods for the Simultaneous Expansion of Multiple Immune Cell Types, Related Compositions and Uses of Same in Cancer Immunotherapy In force Term ends May 21, 2043 · High confidence	In force	Term ends May 21, 2043	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 1 abandoned · 1 no status recorded

List them